omniture
logo
Search
维眸生物科技（浙江）有限公司
Media Room

Latest News

rss

VivaVision Strengthens Scientific Advisory Board with a World-Renowned Expert in Ophthalmology

WENZHOU, China, Aug. 12, 2025 /PRNewswire/ -- Recently, VivaVision Biotech ( Zhejiang) Co., Ltd. (Vi...

2025-08-13 00:00 1760

VivaVision Announces Positive Comments from FDA for the Type C Meeting Regarding VVN461LD for Post-operative Infalmmation - Agreeing the Phase 2 Trial to Be Served as One of the Two Pivotal Studies.

HONG KONG and WENZHOU, China, June 9, 2025 /PRNewswire/ -- VivaVision Biotech (VivaVision), a late ...

2025-06-10 00:00 1923

VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Non-Infectious Anterior Uveitis

* VVN461, a dual JAK1/TYK2 inhibitor as a non-steroidal anti-inflammatory agent, has met primary ...

2025-04-25 00:00 2566

VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Post-Operative Inflammation Following Cataract Surgery

* VVN461, a non-steroidal dual JAK1/TYK2 immunomodulator, achieves primary endpoint, demonstratin...

2024-12-04 00:00 2343

VVN539 met primary study endpoints in US phase IIa clinical study for the treatment of glaucoma

SHANGHAI, June 4, 2023 /PRNewswire/ -- This was a Phase 2, double-masked, randomized, vehicle-contr...

2023-06-05 08:00 2480

VivaVision Biotech Announces Positive Topline Results of VVN001 in the Phase 2 Clinical Study for the Treatment of Dry Eye Disease

SHANGHAI, March 22, 2022 /PRNewswire/ -- VivaVision Biotech, Inc. (VivaVision), an ophthalmic pharm...

2022-03-23 08:00 2136